艾米特里普提林用于预防疹后神经疼痛:ATHENA研究的研究协议
Sian Wells1, Stephanie J MacNeill1, Yumeng Liu1
1Bristol Trials Centre, University of Bristol, Bristol, UK.
Skin health and disease
|March 24, 2025
概括
这项研究调查了低剂量阿米特利普提林是否可以预防带状疹患者的疹后神经疼痛 (PHN). 研究结果将为这种常见并发症的治疗策略提供信息.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 疹后神经疼痛 (PHN) 是疹 (shingles) 的常见和衰弱的并发症.
- 阿米特利普提林是一种三环抗抑郁药,具有针对PHN的潜在预防性.
- 确定预防性低剂量阿米林的疗效对于管理带状疹并发症至关重要.
研究的目的:
- 评估预防性低剂量阿米林在预防新发带状疹患者的PHN中的有效性.
- 为预防PHN进行阿米林的健康经济分析.
- 评估这种预防策略的可接受性并优化其交付.
主要方法:
- 一个多中心的,随机的,安慰剂控制的优越性试验,涉及50岁及以上的新出现带状疹患者.
- 参与者接受了10毫克阿米特利普提林或安慰剂,剂量升级可容忍70天.
- 数据收集包括初级结局 (90天PHN),资源使用,以及来自患者和招聘人员采访的定性数据.
主要成果:
- 主要结局是PHN的存在,使用Zoster简短疼痛库存在皮疹发作后90天进行评估.
- 卫生经济分析将确定每例PHN预防的成本和每年质量调整的生命年成本.
- 定性数据将提供对试验交付,解释和实施的见解.
结论:
- 这项试验代表了迄今为止对预防PHN的低剂量阿米林的最大评估.
- 结果将澄清阿米林在减少PHN的发病率方面的临床和成本效益.
- 这些发现旨在指导治疗带状疹的临床实践和政策.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
145
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
145
01:22Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137